Omni Bio Pharm Inc (OMBP) 0.0325 $OMBP Global Myocardial

New Post Public Reply Private Reply Replies (0) Message Board

May 17, 2015 at 3:09 PM

Omni Bio Pharm Inc (OMBP) 0.0325 $OMBP

Global Myocardial Infarction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6sc3q/myocardial) has announced the addition of the "Myocardial Infarction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alligator Bioscience AB - AstraZeneca PLC - Athersys, Inc. - Bayer AG - CellProthera - Compugen Ltd. - CSL Limited - FibroGen, Inc. - Fina Biotech - Genextra S.p.a. - GlaxoSmithKline plc - GliaMed, Inc. - Hadasit Medical Research Services & Development Ltd - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - LegoChem Biosciences, Inc - LG Life Sciences, Ltd. - Ligand Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Omni Bio Pharmaceutical Inc. - Pluristem Therapeutics Inc. - Polyphor Ltd. - Quantum Genomics SA - Recardio GmbH - Remedy Pharmaceuticals, Inc. - Targazyme, Inc. - Vicore Pharma AB - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/m6sc3q/myocardial
PSTI: 2.68 (-0.01), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), CGEN: 6.45 (-0.03), FGEN: 20.38 (-1.01), GSK: 44.77 (-0.22), ATHX: 1.27 (-0.01)

Global Graft Versus Host Disease (GVHD) Pipeline Report 2015 - Analysis of 43 Companies & 66 Drug Profiles
M2 - Mon Apr 27, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjmb6v/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Adienne Pharma & Biotech - Alder Biopharmaceuticals Inc. - Alexion Pharmaceuticals, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bellicum Pharmaceuticals, Inc. - Biogen Idec Inc. - Dr. Falk Pharma GmbH - Enlivex Therapeutics Ltd - Escape Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Generon (Shanghai) Corporation Ltd. - Lycera Corp. - Mesoblast Limited - Millennium Pharmaceuticals, Inc. - MSM Protein Technologies, Inc. - Neopharm Ltd. - NeoStem, Inc. - Novartis AG - Omni Bio Pharmaceutical Inc. - Pharmacyclics, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - R-Tech Ueno, Ltd. - REGiMMUNE Corporation - Targazyme, Inc. - Therapix Biosciences Ltd - Tobira Therapeutics, Inc. - Xenikos B.V. For more information visit http://www.researchandmarkets.com/research/bj...ersus_host
BIIB: 391.24 (-3.11), PCYC: 255.42 (-0.50), PSTI: 2.68 (-0.01), NBS: 2.38 (+0.07), ALDR: 39.84 (+4.35), BLCM: 23.02 (-1.37), ALXN: 160.56 (-1.13), ATHX: 1.27 (-0.01), TBRA: 14.00 (+0.55), NVS: 103.75 (-0.15)

Omni Bio Announces Presentation of Phase 1/2 Clinical Data for AAT at American Heart Association Scientific Sessions
Marketwired - Wed Nov 19, 3:20PM CST
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio"

, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the presentation of Phase 1/2 clinical data for plasma-derived alpha-1 antitrypsin ("p-AAT"

, demonstrating its ability to inhibit the inflammatory response in patients with acute ST-elevation myocardial infarction ("STEMI"

, the most severe type of heart attack. The data were presented yesterday in a poster at the American Heart Association Scientific Sessions 2014, in Chicago. Importantly, these latest clinical findings further highlight the potential value of Omni Bio's first-in-class recombinant AAT candidate, AAT-Fc.

Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic
Marketwired - Wed Nov 19, 3:18PM CST
Omni Bio Pharmaceutical, Inc. (OTCBB: OMBP) ("Omni Bio"

, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today its manufacturing partners, Patheon and Sigma-Aldrich Fine Chemicals (SAFC), have successfully identified several high-expression cell lines able to produce Omni Bio's novel recombinant alpha-1 antitrypsin molecule (AAT-Fc) in large enough quantities to be considered commercially viable. This is a highly significant de-risking milestone that enables Omni Bio to move toward IND-enabling toxicology studies with the first and only pharmaceutically feasible recombinant AAT candidate currently in development.

Omni Bio to Present at 7th Annual BioPharm America Conference
Marketwire - Tue Sep 16, 8:03AM CDT
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio"

, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today that it will present at the 7th Annual BioPharm America(TM) 2014 conference, September 22-24, held at the Boston Marriott Copley Place in Boston, MA.

Omni Bio Appoints Jack Riccardi as Chief Financial Officer
Marketwire - Thu Aug 14, 8:03AM CDT
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio"

, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the appointment of Jack Riccardi as its Chief Financial Officer. Mr. Riccardi brings more than 30 years of financial leadership experience. He was formerly CFO of ADial Pharmaceuticals and served most recently as CFO and Partner at Green Street Ventures. Mr. Riccardi's appointment will become effective on September 1, 2014.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GTEC Faces Nasdaq Bid Price Compliance Challenge

Greenland Technologies in a Tight Spot Man, stocks can be as unpredictable as a cat on a hot tin roof, and Greenland Technologies Holding Corporation (Nasdaq: GTEC) just got a cold splash of reality from Nasdaq. On November 10, 2026, they were handed a Notification Letter that ain’t exactly a love note. Their shares slipped below the one-buck hurdle, and Nasdaq isn’t...

SOCSA: The Future of Safety in Confined Spaces?

Autonomous Tech Meets Safety Regulations Some days innovation hits like a ton of bricks, and here we go again—this time with a gizmo aiming to shake up the safety game in confined spaces. Enter the SOCSA, the Self Operating Confined Space Attendant, designed by a seasoned agriculture worker who's had a ringside seat to enough OSHA rule breaches to fill a book. But ain't...

Perennial Housing Group's Big Move into Affordable Housing

Perennial's Ambitious Entry into the Affordable Housing Scene They say the real estate game's all about location, but when you’re diving into affordable housing, it's about necessity too. Perennial Housing Group, under the helm of seasoned CEO Gregory B. Jones, is kicking things off with a hefty acquisition—31 affordable housing communities spread across the Southeast...

Japanese Craftsmanship Shines at Kyoto Exhibition

Kyoto's Artistic Fiesta: Tradition Meets Innovation In the soul of Kyoto, where ancient temples brush shoulders with bustling streets, the "Mastery of Touch, Mystery of Time" exhibition unfolded like a well-worn storybook, revealing page after page of Japan's enduring craftsmanship. Held at the stately Kyoto State Guest House on November 7-8, 2026, this exclusive...

Classic vs. Youngtimer Cars: Evolution in Collecting

The Collector's Journey: Classic Cars vs. Youngtimers Ever notice how car collecting has its own circles of fame? You're either basking in the glow of a vintage classic or eyeing a youngtimer that’s just catching steam. In this article from HelloNation, Engels Gualdani — the classic car sage of Hilton, NY — helps untangle these categories for us, and it’s a lesson...

Fluence Energy Faces Class Action: Investor Insights

Investor Blues: Fluence Under the Weather If you've been keeping an eye on Fluence Energy (NASDAQ:FLNC), you're probably clutching your metaphorical pearls right now. Here's the scoop: on November 2, 2026, the stock took another nosedive—dropping nearly 9%—as the company announced that both CEO Julian Nebreda and CFO Ahmad Pasha had packed their bags. A leadership...

City National Bank Names New VP for Real Estate

Banking on Growth with Jeffrey LaBauve Jeffery LaBauve struts into the picture, ready to take the helm as City National Bank's new head of Commercial Real Estate Banking. And let me tell ya, the word on the street is he's raring to ramp things up. After almost two decades at Comerica Bank, this guy’s not here for a measly lap around the track—he's got plans to double...

Business Boom in 2026: Key Regions to Watch Now

Business Formations Break Records in 2026 I'm telling you, the entrepreneurial spirit is alive and kicking across the States this year. The latest numbers from Registered Agents Inc are clear as day: business is bustling. We're looking at 576,818 new business setups nationwide just in October 2026. That's outpacing the previous year by a whopping 8%. And if that doesn't...

Willamette Valley's Q3 Struggle: Revenue Gains Amid Losses

Navigating the Q3 Highs and Lows When you look at Willamette Valley Vineyards, it feels like they're stuck on a tricky grapevine. Their Q3 results for 2026 dropped like a brick, showing a $0.33 loss per share. It's a carbon copy of last year's blues, without any sweet surprise. Now don't get me wrong, the 6.6% revenue bump is a peach, but all we got was a slightly rosier...

Global Energy Storage Colloquium Sparks Collaboration

Setting the Stage for Energy Storage Breakthroughs Imagine a room bustling with brainpower, brimming with the promise of cleaner, more efficient energy. That's the scene at the inaugural Global Energy Storage Colloquium in Xiamen, where top-tier experts from all corners gathered to uncover what's next for energy storage. We're not just talking new gadgets but giant leaps...